← All countries · Europe
88%
MCV1
2025 · WHO/UNICEF estimate
92%
DTP3
2025 · WHO/UNICEF estimate
92%
IPV complete
2025 · WHO/UNICEF estimate
89%
HepB3
2025 · WHO/UNICEF estimate
2
Measles cases
2025 reported
88
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 86%2025 · WHO/UNICEF estimate | 94.5% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 97%2025 · WHO/UNICEF estimate | 96.9% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 92%2025 · WHO/UNICEF estimate | 91.7% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 97%2025 · WHO/UNICEF estimate | 96.9% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 92%2025 · WHO/UNICEF estimate | 91.7% | C · weak | |
| MCV1First dose of measles-containing vaccine | 88%2025 · WHO/UNICEF estimate | 88.3% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 82%2025 · WHO/UNICEF estimate | 82.1% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 88%2025 · WHO/UNICEF estimate | 88.3% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 89%2025 · WHO/UNICEF estimate | 89.3% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 87%2025 · WHO/UNICEF estimate | 95.3% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 90%2025 · WHO/UNICEF estimate | 90.1% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 95.3%2025 · Administrative (country-reported) | 95.3% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 86%2025 · WHO/UNICEF estimate | 85.5% | A · strong | |
| RotaCRotavirus vaccine, complete series | 61%2025 · WHO/UNICEF estimate | 60.5% | B · good | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 14%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 9%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 3%2025 · WHO/UNICEF estimate | — | too few points | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 22025 | 0.3per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 42025 | 0.6per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 882025 | 13.1per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 12025 | 0.1per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 162025 | 2.4per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 12025 | 0.1per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (44 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | |
| BCGBCG (Baccille Calmette Guérin) vaccine | 2 | Y7 | General/routine | |
| CCHFCCHF (Crimean-Congo Hemorrhagic Fever) vaccine | 1 | Y16 | Health workers · SUBNATIONAL | Health facility staff in endemic regions |
| CCHFCCHF (Crimean-Congo Hemorrhagic Fever) vaccine | 1 | Y16 | Risk group(s) · SUBNATIONAL | Health facility staff in endemic regions |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPDTaP (acellular) vaccine | 1 | Pregnant women | Pregnant women | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | W6 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | W10 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | W14 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 4 | M16 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y6 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | Immunization against Hepatitis B is part of National Im schedule. If monovalent vaccine is used the scheme is 0-1-6 months. Is hexavalent vaccine is used the scheme is described below. Regardless the used vaccine the first dose within 24 hours after birth is obligatory. |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M1 | General/routine | Immunization against Hepatitis B is part of National Im schedule. If monovalent vaccine is used the scheme is 0-1-6 months. Is hexavalent vaccine is used the scheme is described below. Regardless the used vaccine the first dose within 24 hours after birth is obligatory. |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M6 | General/routine | Immunization against Hepatitis B is part of National Im schedule. If monovalent vaccine is used the scheme is 0-1-6 months. Is hexavalent vaccine is used the scheme is described below. Regardless the used vaccine the first dose within 24 hours after birth is obligatory. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y10-Y14 | HPV administered to females and males | 9 valent vaccine administered; girls aged 10-14 years and boys 10-13 years in line with National program for primary prophylaxis of HPV associated cancers 2025-2030 |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | Y10-Y15 | HPV administered to females and males | 9 valent vaccine administered; girls aged 10-14 years and boys 10-13 years in line with National program for primary prophylaxis of HPV associated cancers 2025-2030 |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons >65 years |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M13 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y12 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | W6 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | W14 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M12 | General/routine | |
| RABIESRabies vaccine | 1 | Risk group(s) | As pre-exposure prophylaxis for veterinary specialists, forestry workers, agricultural workers, hunters, fur pullers, employees in zoos and shelters for stray dogs, staff of slaughterhouses and incinerators- and post-exposure prophylaxis | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | W6 | General/routine | 1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for rotavirus prophylaxis in Bulgaria 2022-2025 |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | W10-W24 | General/routine | 1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for rotavirus prophylaxis in Bulgaria 2022-2025 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | W6 | General/routine | 1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for rotavirus prophylaxis in Bulgaria 2022-2025 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | W10-W24 | General/routine | 1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for rotavirus prophylaxis in Bulgaria 2022-2025 |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | W20-W32 | General/routine | 1 and 5 valent vaccine administered; the vaccines are free of charge for newbornes in line with National program for rotavirus prophylaxis in Bulgaria 2022-2025 |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y12 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y17 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | Y25 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | Y35 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | Y45 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | Y55 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y65 | Adults |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.